MicroRNA-30c-5p Inhibits NLRP3 Inflammasome-mediated Endothelial Cell Pyroptosis Through FOXO3 Down-regulation in Atherosclerosis
Overview
Affiliations
Atherosclerosis is a chronic inflammatory disease involved in endothelial dysfunction. Pyroptosis is a pro-inflammatory form of cell death and plays pivotal roles in atherosclerosis. MicroRNAs (miRNAs) are implicated in atherosclerosis, however the mechanisms that underlie miR-30c-5p is required for endothelial cell pyroptosis remain elusive. In the present study, we probed the interaction of miR-30c-5p with forkhead box O3 (FOXO3) and investigated the effect of miR-30c-5p and FOXO3 on NLRP3 inflammasome and endothelial cell pyroptosis. Introduction of oxidized low density lipoprotein (ox-LDL) dose-dependently increased lactate dehydrogenase (LDH) release as well as pyroptosis in human aortic endothelial cells (HAECs). On the basis of ox-LDL treatment, we found the expression of miR-30c-5p was impaired and enrichment of miR-30c-5p protected HAECs from ox-LDL-induced pyroptosis. Moreover, addition of miR-30c-5p inhibited ox-LDL-activated NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, which was associated with HEACs pyroptosis. Nevertheless, miR-30c-5p failed to show efficacy of Toll-like receptor (TLR) signaling of NLRP3 inflammasome activation. Intriguingly, FOXO3 was suggested to be targeted by miR-30c-5p and addition of miR-30c-5p blocked FOXO3 expression, whereas miR-30c-5p depletion showed opposite effects. Furthermore, silencing of FOXO3 inhibited NLRP3-mediated pyroptosis and reversed anti-miR-30c-5p-induced activation of NLRP3 inflammasome and pyroptosis in HEACs with ox-LDL treatment. Our finding suggested that miR-30c-5p might play essential role in NLRP3 inflammasome-modulated cell pyroptosis by targeting FOXO3 in HAECs, providing a novel therapeutic avenue for atherosclerosis treatment.
Radmehr E, Yazdanpanah N, Rezaei N J Transl Med. 2025; 23(1):249.
PMID: 40022088 PMC: 11871836. DOI: 10.1186/s12967-025-06269-w.
Chang B, Zhang X, Fang R, Li H, Zhou Y, Wang Y J Cardiothorac Surg. 2025; 20(1):12.
PMID: 39755617 PMC: 11699799. DOI: 10.1186/s13019-024-03258-w.
Su Y, Lu C, Chen S J Immunol Res. 2024; 2024:1429510.
PMID: 39512836 PMC: 11540895. DOI: 10.1155/2024/1429510.
Extracellular vesicle-encapsulated miR-30c-5p reduces aging-related liver fibrosis.
Rodrigues A, Heng Y, Slack F Aging Cell. 2024; 23(12):e14310.
PMID: 39269881 PMC: 11634720. DOI: 10.1111/acel.14310.
NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies.
Chen P, Li X Front Pharmacol. 2024; 15:1430236.
PMID: 39144618 PMC: 11322363. DOI: 10.3389/fphar.2024.1430236.